Table 2.
Patient characteristics stratified by study period
|
Characteristic |
Period A (n= 151)* |
Period B (n= 123) |
P-value |
||
|---|---|---|---|---|---|
| n | (%) | n | % | ||
| Median age, years |
50 |
|
51 |
|
0.33 |
| Histology |
|
|
|
|
|
| Inflammatory |
25 |
(17) |
27 |
(22) |
|
| Non-Inflammatory |
126 |
(83) |
96 |
(78) |
0.59 |
| Site of Metastasis |
|
|
|
|
|
| Liver |
28 |
(19) |
45 |
(37) |
0.30 |
| Lung |
45 |
(30) |
39 |
(32) |
0.24 |
| Brain |
4 |
(3) |
10 |
(8) |
0.72 |
| Bone |
84 |
(56) |
82 |
(67) |
0.008 |
| Bone Only |
37 |
(25) |
31 |
(25) |
0.52 |
| Supraclavicular Node |
55 |
(36) |
34 |
(28) |
0.20 |
| Soft tissue |
20 |
(13) |
22 |
(18) |
0.18 |
| ER Status |
|
|
|
|
|
| Positive |
56 |
(63) |
75 |
(68) |
|
| Negative |
33 |
(37) |
34 |
(32) |
0.01 |
| PR Status |
|
|
|
|
|
| Positive |
43 |
(48) |
54 |
(51) |
|
| Negative |
45 |
(52) |
53 |
(49) |
0.75 |
| HER2 Status |
|
|
|
|
|
| Positive |
1 |
(50) |
31 |
(39) |
|
| Negative |
1 |
(50) |
32 |
(62) |
0.71 |
| Receipt of Endocrine therapy |
|
|
|
|
|
| SERMs |
82 |
(54) |
52 |
(42) |
0.0002 |
| AI |
19 |
(13) |
46 |
(37) |
0.72 |
| LHRH |
0 |
(0) |
5 |
(4) |
0.87 |
| Fulvestrant |
2 |
(1) |
19 |
(15) |
0.86 |
| Receipt of Chemotherapy |
|
|
|
|
|
| Category A** |
85 |
(56) |
15 |
(12) |
|
| Category A + B |
32 |
(21) |
95 |
(77) |
<0.0001 |
| Receipt of HER2-directed therapy |
2 |
(1) |
19 |
(15) |
0.17 |
| Receipt of Bisphosphonates |
|
|
|
|
|
| Pamidronic acid |
8 |
(5) |
37 |
(30) |
0.0007 |
| Zoledronic acid | 3 | (2) | 35 | (28) | 0.04 |
Percentages reflect the proportion of patients in each subgroup relative to the total number of patients in the respective period (i.e., Period A or Period B), except for ER, PR, and HER2 status. For these variables, percentages reflect the proportion of patients in each subgroup relative to the total number of patients in the respective period for whom pathologic data is available. P-values determined using the Chi-square test.
* Period A encompasses patients diagnosed between January 1, 1985 and December 31, 1994. Period B encompasses patients diagnosed between January 1, 1995 and December 31, 2004.
** See Table 1 for delineation of cytotoxic agents within Category A and Category B.